CYT006-AngQb
| Vaccine description | |
|---|---|
| Target | Hypertension |
| Vaccine type | Conjugate |
| Clinical data | |
| Routes of administration | Subcutaneous |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| ChemSpider |
|
  (what is this?) (verify) | |
CYT006-AngQb was an investigational
Method of action
Angiotensin II causes blood vessels to constrict, and drives blood pressure up. CYT006-AngQb consists of virus-like particles
Studies
In a 2008 phase IIa study, 72 patients received 100 μg, 300 μg or placebo in weeks 0, 4, and 12. Blood pressure was lowered dose-dependently, by 5.6 mmHg (systolic) and 2.8 mmHg (diastolic) in the 300 μg group. Morning blood pressure (5:00-8:00) was lowered by 25 mmHg (systolic) and 13 mmHg (diastolic).
Side effects were mild and included local reactions, headache and fatigue.[2]
The 2008 trial was small and exploratory. It did not address the question of whether the vaccine actually protects internal organs, nor did it address safety concerns such as whether the vaccine would cause autoimmune disease. If a standard drug treatment is found to dangerously inhibit the renin-angiotensin-aldosterone system, it can be withdrawn and the effects reversed quickly, but that would not be true of the vaccine. However, poor compliance to standard treatment is the main reason for inadequate control of blood pressure, and if vaccination were safe and effective in the long run, it may solve many compliance problems.[3]
CYT006-AngQb did not reach Phase III studies because the antihypertensive effects were small compared to existing